🇺🇸·6h agoResearch
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
Publisher
A
ASCO JCO Journal
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ASCO JCO Journal
- Region
- USA
- Scope
- Research
- Published
- June 20, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ascopubs.org
Leave the platform to read the original full article on the publisher site.
Source: ASCO JCO Journal
Scope: Research
Related coverage
More related coverage
ASCO JCO Journal/6h ago
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1
ASCO JCO Journal/6h ago
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1
ASCO JCO Journal/6h ago
Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma
ASCO JCO Journal/6h ago